[Control of calcium and phosphate in hemodialysis patients]

Area of Science:

• Nephrology
• Endocrinology
• Mineral and Bone Disorder

Context:

• Hemodialysis patients often exhibit mineral and bone disorder, with elevated serum calcium and low intact parathyroid hormone (PTH) levels, failing to meet K/DOQI guideline targets.
• Traditional calcium-based phosphate binders can exacerbate hypercalcemia in this population.

Purpose:

• To evaluate the efficacy of sevelamer hydrochloride in conjunction with diet therapy for improving mineral and bone disorder management in hemodialysis patients.
• To assess the impact of medication adjustment and dietary changes on achieving target levels for calcium, phosphate, calcium x phosphate product, and intact PTH.

Summary:

• Implementing sevelamer hydrochloride reduced the need for calcium-based phosphate binders, leading to decreased serum calcium and increased intact PTH levels.
• A combined approach of diet therapy and medication adjustment resulted in a significant increase in the percentage of patients meeting all K/DOQI targets, from 1.7% to 14.7%.
• The study highlights the critical role of both medical and dietary interventions in optimizing mineral metabolism, particularly in patients with longer dialysis durations or parathyroid gland abnormalities.

Impact:

• Demonstrates a successful strategy for improving mineral and bone disorder control in hemodialysis patients, enhancing adherence to clinical guidelines.
• Provides evidence for the utility of sevelamer hydrochloride as a valuable therapeutic option for managing hypercalcemia and secondary hyperparathyroidism.
• Underscores the importance of personalized and comprehensive management plans, integrating pharmacological and nutritional approaches for better patient outcomes.